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While several clinical prediction rules (CPRs) of survival exist for patients with symptomatic
spinal metastasis (SSM), these have variable prognostic ability and there is no recognized
CPR for health related quality of life (HRQoL). We undertook a critical appraisal of the litera-
ture to identify key preoperative prognostic factors of clinical outcomes in patients with SSM
who were treated surgically. The results of this study could be used to modify existing or
develop new CPRs.
Methods
Seven electronic databases were searched (1990–2015), without language restriction, to
identify studies that performed multivariate analysis of preoperative predictors of survival,
neurological, functional and HRQoL outcomes in surgical patients with SSM. Individual stud-
ies were assessed for class of evidence. The strength of the overall body of evidence was
evaluated using GRADE for each predictor.
Results
Among 4,818 unique citations, 17 were included; all were in English, rated Class III and
focused on survival, revealing a total of 46 predictors. The strength of the overall body of evi-
dence was very low for 39 and low for 7 predictors. Due to considerable heterogeneity in
patient samples and prognostic factors investigated as well as several methodological
issues, our results had a moderately high risk of bias and were difficult to interpret.
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Conclusions
The quality of evidence for predictors of survival was, at best, low. We failed to identify stud-
ies that evaluated preoperative prognostic factors for neurological, functional, or HRQoL
outcomes in surgical patients with SSM. We formulated methodological recommendations
for prognostic studies to promote acquiring high-quality evidence to better estimate predictor
effect sizes to improve patient education, surgical decision-making and development of
CPRs.
Introduction
Symptomatic spinal metastasis (SSM) afflicts up to 10% of cancer patients[1–3], of which
approximately 10% are surgically managed.[4] Given that over 14 million Americans lived
with a diagnosis of cancer in 2014 and almost 19 million are expected to do so by 2024[5], the
number of cancer survivors expected to undergo surgery for SSM will increase by approxi-
mately 36% over the next 10 years.
Since the randomized controlled trial conducted by Patchell et al.[6] showing that surgery
followed by radiotherapy provided superior neurologic outcomes compared to radiotherapy
alone in patients suffering from a single cervical or thoracic SSM with a life expectancy of 3
months, this life expectancy threshold has been widely adopted in decision-making for surgical
treatment.[7–9] However, clinicians and surgeons tend to estimate survival in patients with
advanced cancer inaccurately.[10–13] Also, although several studies reported that surgical
intervention improved health related quality of life (HRQoL)[6, 9, 14–20], SSM treated with
surgery is the most costly skeletal-related event in patients with cancer.[21]
Clinical prediction rules (CPRs), which combine various clinical factors from an individual
with a given health state and provide an estimate of the risk of experiencing a specific endpoint
within a certain period[22], may allow physicians to make more precise clinical estimates and
thus assist therapeutic decision-making and counselling.[22, 23] Although several CPRs of sur-
vival have been elaborated, we are not aware of any CPR for HRQoL for SSM patients. Also,
current CPRs of survival have variable prognostic ability.[24–26] This may be due to differ-
ences between patient samples that were used to generate and conduct prognostic value assess-
ment. For instance, Bartels et al.[27] created a CPR of survival based on a cohort of patients
who received radiotherapy. In their most recent external validation study[28], misspecification
of their model was attributed to the surgical patient subgroup.
The majority of published series assessed preoperative predictors of survival rather than
HRQoL. We conducted a systematic review to ascertain the preoperative prognostic factors for
1) survival, 2) neurologic status, 3) functional status, and 4) HRQoL in surgical SSM patients.
We also appraised the methodology and reporting of prognostic studies that met our eligibility
criteria. The results of this study could not only be used to modify existing CPRs of survival to
improve their prognostic value, but also to improve the theoretical framework to develop new
CPRs for survival and HRQoL outcomes specific to surgical SSM patients.
Methods
This systematic review and best-evidence synthesis was conducted and reported in accordance
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines[29]. In compliance with the guidelines, our systematic review protocol was
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registered with the International Prospective Register of Systematic Reviews (PROSPERO)[30]
on June 24th, 2015 and was last updated on July 12th, 2016 (registration number
CRD42015023831).
Literature search
In adult patients who underwent surgery for SSM, we sought to answer the following four key
questions (KQs): What are the preoperative clinical factors associated with postoperative (1)
survival; (2) neurologic status, such as muscle power on the Medical Research Council (MRC)
scale for testing muscle strength, neurologic outcome measures (e.g. American Spinal Injury
Association (ASIA) or Frankel grade) or autonomic functions (bladder / bowel control); (3)
functional status, in terms of ambulatory status, functional outcome measures, such as func-
tional independence measure (FIM), Barthel index, Eastern Cooperative Oncology Group
(ECOG) or Karnofsky performance status (KPS); and (4) HRQoL, in terms of score on any
HRQoL measure, such as short form health survey (SF-36), EuroQol 5 dimensions (EQ-5D) or
Oswestry Disability Index (ODI)?
The electronic databases MEDLINE, MEDLINE in Process, Embase, Web of Science,
CINAHL, Cochrane Central Register of Controlled Trials, and Scopus were systematically
searched for studies performed in humans from January 1, 1990 to December 31, 2015 with no
language restrictions applied. The search strategies were developed in consultation with infor-
mation specialists at the University Health Network Health Sciences Libraries. S1 Table pres-
ents our complete search strategies. The reference lists of studies meeting the eligibility criteria
and relevant review papers were manually screened for additional studies.
Eligibility criteria
Citations were screened for eligibility by following a priori determined inclusion and exclusion
criteria (Table 1). Original studies with an identifiable surgical treatment arm or surgical
cohort of at least 30 patients, who underwent de novo spinal surgery for a single symptomatic
metastatic spinal lesion, with a postoperative follow-up of at least 6 months, published in peer-
reviewed journals included in Ulrichsweb[31] at the time of publication, describing and
reporting both the preoperative prognostic clinical factors assessed and the univariate and
multivariate analyses conducted, were considered for inclusion. Studies that included surgical/
postoperative predictors in their multivariate analyses, patients < 18 years old, patients oper-
ated for recurrent SSM or primary spinal tumor were excluded.
Screening and selection
All duplicates were removed using EndNote X4 followed by manual elimination. Two authors
(AN and ARM) independently (1) screened the titles and abstracts to identify potential eligible
studies to undergo full-text assessment and then (2) reviewed the selected full-text articles for
final inclusion. Discrepancies between the two reviewers were resolved by consensus agree-
ment; persisting disagreements were settled by consulting the senior author (MGF).
Data extraction and synthesis
The following data were extracted by AN and then checked by ARM: 1) first author and publi-
cation date; 2) publication language; 3) study design; 4) purpose; 5) patient sample and charac-
teristics, with relevant inclusion and exclusion criteria; 6) preoperative predictors 7) outcome
assessed; 8) postoperative follow-up characteristics, including length, rate, and information
about how missing data were handled; 9) methodology, including details related to predictors’
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Table 1. Inclusion and exclusion criteria.
Inclusion Exclusion
Patient De novo surgically treated adults MESCC patients included in a
surgical series of at least 30 patients published from January 1, 1990
to December 31, 2015
• MESCC due to trauma, infection, stenosis, degenerative changes,
primary CNS or vertebral tumor
• Pediatric (< 18 years)
Intervention Surgical treatment1 performed for at least one of the following
indications:
• Intractable pain resulting from a symptomatic MESCC lesion
• Spinal instability: imminent or overt
• Onset or progression of neurologic deficits, i.e. sensorimotor or
autonomic
• All non-surgical treatments (hormonotherapy, immunotherapy,
chemotherapy, corticosteroid, and radiotherapy, including
conventional external beam radiotherapy, intensity-modulated
radiotherapy, stereotactic radiosurgery / stereotactic body
radiation therapy, stereotactic radiotherapy and systemic
application of radioisotopes) used alone




• From all languages and at the time of publication, published in
peer-reviewed journals between January 1, 1990 to December 31,
2015
• Prospective and retrospective studies with a follow-up of at least
six months
• With an identifiable surgical treatment arm or surgical cohort of at
least 30 patients
• Providing adequate description of pre-operative factors2
• With adequate description of the (1) preoperative predictive
clinical factors assessed and (2) univariate and multivariate
analyses conducted
• With the results of univariate and multivariate analyses clearly
reported
Studies that used the same data were individually included as long
as they satisfy our eligibility criteria
Studies validating or examining the accuracy of existing scoring
systems were included if (1) they met the eligibility criteria, (2)
patient sample was different from the one used to develop the
scoring system (3) and the predictive value of the preoperative
clinical factors constituting the scoring system were individually
assessed and clearly reported.







• Studies that involved multivariate analysis that included surgical or




• sphincter dysfunction, i.e. bladder and bowel control
• sexual dysfunction
• ASIA or Frankel score
• Functional outcomes
• Karnofsky / ECOG performance status
• Ambulatory status
• Quality of life
• Score on any given metrics or instruments assessing health
related quality of life
1 Spinal surgery refers to a de novo surgical treatment involving any open or minimally invasive spinal interventions, including vertebroplasty and
kyphoplasty, to achieve partial or complete spinal decompression and/or mechanical stabilization, with or without instrumentation
2 Potential pre-operative predictive factors include clinical features such as sex, age, ethnicity, body mass index (BMI), smoking status, histologic type or
site of the primary tumor, biomarkers, treatment received for primary and/or spinal metastasis, performance status score and SF-36. Potential surgical
predictive factors include type of surgery and extent of tumor resection, length of operation and blood loss.
ASIA: American Spinal Injury Association; ECOG: Eastern Cooperative Oncology Group; MESCC: metastatic epidural spinal cord compression
doi:10.1371/journal.pone.0171507.t001
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selection, type of univariate and multivariate analyses conducted, multivariate modeling pro-
cess and assumption(s) testing; and 10) univariate and multivariate estimates, including
reported odds / hazard ratios and confidence intervals. Unless otherwise specified, a p-
value < 0.05 was considered statistically significant.
Critical appraisal of the literature
We are not aware of any consensus regarding a standardized approach for assessing the quality
of prognostic studies.
Risk of bias in individual studies
AN and ARM independently assessed the risk of bias of individual articles (Class I to IV) using
the method described by Skelly et al.[32, 33] for prognostic studies (S2 Table). The final class-
of-evidence rating was assigned following consensus agreement.
Risk of bias across studies: Overall quality of evidence
Once all articles were individually evaluated, the strength of the overall body of evidence with
respect to each predictor was allocated using the approach developed by the Grading of Rec-
ommendation Assessment, Development and Evaluation (GRADE) Working Group.[34] The
baseline strength of the overall body of evidence was assigned “High” if the majority of the
studies were Class I or II and “Low” if the majority of the studies were Class III or IV. The
strength could then be downgraded by one or two levels based on the risk of bias, consistency,
directness, precision and publication bias. Alternatively, the strength could be upgraded by
one or two levels if the effect was large, there was evidence of a dose response gradient or all
plausible confounders would either reduce a demonstrated effect or would suggest a spurious
effect when the results showed no effect. The final strength of the overall body of evidence for
each predictor was classified as High, Moderate, Low or Very Low and expresses our confi-
dence that the evidence reflects the true effect and the likelihood of further research to change
our confidence in the latter estimate of effect (S3 Table). Overall, this method adheres to the
general principles described by Hayden et al.[35] for assessing the quality of prognostic studies
in systematic reviews.
Results
The search yielded 4,818 unique citations, of which the title and abstract were screened, lead-
ing to the selection of 152 articles for full-text review. Among these, a total of 135 studies were
excluded for one of the following reasons: preoperative prognostic factors were not evaluated
or were assessed as part of a scoring system and not evaluated individually; multivariate analy-
sis was not conducted; multivariate analysis included surgical and/or postoperative factors as
predictors; the journal was not peer-reviewed at the time of publication on Ulrichsweb[31];
surgical patients were not evaluated separately from non-surgical patients; the study included
less than 30 surgical patients; spinal metastases were not distinguished from extraspinal bony
metastases; patient sample included patients < 18 years of age; the study involved metastasis
from primary central nervous system tumors; postoperative follow-up was less than six
months. No additional studies were added after manually checking reference lists (Fig 1).
All 17 articles meeting our eligibility criteria were published in English and addressed KQ1,
i.e. the preoperative clinical factors associated with survival in surgical SSM patients. There
were six additional studies that examined the clinical prognostic factors of functional status
(KQ3) in terms of the ability to walk[36–41] or regaining the ability to walk[37]
Symptomatic spinal metastasis – a systematic review
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Fig 1. Study selection process.
doi:10.1371/journal.pone.0171507.g001
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postoperatively and one study that isolated key predictors of survival (KQ1) and HRQoL
(KQ4) using the postoperative EQ-5D score as the dependent variable[42]. However, these
studies included surgical and/or postoperative factors in their multivariate analysis, leading to
their exclusion from this review.
Survival
All 17 studies investigated the prediction of survival, pursuing one or more of the following
aims: to evaluate (1) predictors of survival; (2) predictors of survival and propose a prognostic
model or a scoring system to predict survival; (3) the prognostic value of parameters included
in an existing scoring system that predict survival. Ten studies examined aim #1[43–52],
including four that analyzed a heterogeneous population of primary tumor types[43–45, 50],
one study focused on patients older than 60 years of age[46], and the remainder investigated
specific primary malignancy types including breast cancer[48], hepatocellular carcinoma
(HCC)[52], prostate cancer[49] or non-small cell lung cancer (NSCLC)[51] and unknown pri-
mary[47]. Four studies addressed aim #2[41, 53–55], including one that involved a heteroge-
neous primary tumor type[53], prostate cancer[54], lung cancer[55] or NSCLC[41]. Four
studies explored aim #3[24, 52, 56, 57], with three involving heterogeneous primary tumor
type[24, 56, 57] and one focused on HCC[52].
Risk of bias of individual studies
Prospective prognostic studies meeting the following criteria for a good-quality cohort study
are considered Class I evidence: (1) patients were followed for sufficient periods in order that
outcomes could occur, (2) follow-up rate was 80%, (3) patients were at similar point in the
course of their disease, and (4) the study accounted for other prognostic factors (S2 Table).
Although this review included three prospective studies[24, 47, 56], they were considered as
Class III evidence due to violation of two of the criteria for good-quality cohort studies: follow-
up period and drop-out rate were not clearly specified. The remaining 14 retrospective studies
were also considered Class III due to violation of at least one of the criteria for good-quality
studies.
Results of individual studies
A summary of the 17 studies is presented in Table 2. Numerous preoperative clinical factors
were reported to negatively impact survival when all sites of primary tumor were considered:
primary tumor type (e.g. lung, colon)[43, 45, 56], radioresistant primary tumor[50], primary
tumor Tomita Grade III (modified Tomita classification[57] and original classification)[24],
primary tumor Tomita Grade II and III (original classification)[53], poor prognosis of primary
tumor (based of median survival < 20 months[44]), presence of visceral metastasis[24, 53, 56,
57], KPS< 80%[56, 57], presence of neurologic deficit (e.g. palsy)[43, 44], presence of non-
symptomatic spinal metastasis[53, 56], incapacity to walk independently or with a walking
aid[50], Charlson comorbidity index score (CCIS) 2[50], older age[43], male sex[43], pres-
ence of pain[44], and ASIA score B or C[45]; and a score of 9–12 points on the original Toku-
hashi scoring system and primary tumor Tomita Grade III (original classification)[46] in
patients 60 years old.
Prognostic factors for survival varied substantially according to primary tumor types, with
negative relationship as follows: breast cancer with shorter time interval from cancer diagnosis
to SSM surgery, emergency hospital admission, primary tumor with poor/undifferentiated his-
tologic grade and negative progesterone receptors[48]; HHC with low serum albumin and
high lactate dehydrogenase [52]; prostate cancer with KPS 50–70%[54], Gleason score > 8
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[49], total number of metastases > 5[49], presence of lymph node metastases[49], and degree
of canal compression > 25%[49]; lung cancer with presence of visceral metastasis, 14 days
from onset of motor deficit to surgery, incapacity to walk independently or with a walking aid
[55]; NSCLC with KPS< 80%[51], ECOG 3–4[41], 3 vertebral metastases[41], presence of
visceral metastasis[41] and 14 days from onset of motor deficit to surgery[41]; and unknown
site of primary tumor with cervical spinal location, Frankel score A, B or C, and presence of
extraspinal disease at presentation[47].
Methodological issues
All 17 studies used the Cox proportional hazards (PH) regression method for their multivari-
ate survival analysis. Five studies[24, 43, 46, 47, 49] did not provide a clear definition, measure-
ment or categorization of their predictors, e.g. “High versus Intermediate versus Low KPS”
without defining the corresponding KPS numerical range. One study[50] identified CCIS 2
as a predictor of survival although CCIS 2 is not a discriminatory factor given that the sole
presence of metastatic solid tumor gives a CCIS of 6[58]. Four studies[43, 44, 49, 53] did not
clearly report which predictors were assessed using univariate analysis and, among these stud-
ies, one[49] did not report any results for these analyses. Three studies[52, 53, 57] did not spec-
ify how predictors were selected to enter the multivariate analysis. Four studies[24, 48, 50, 51]
did not analyze predictors that were described in the Methods section, and two studies[47, 53]
did not clearly distinguish the results from uni- and multivariate analyses. Only three[43, 48,
50] studies mentioned testing for the proportional hazards assumption (PHA). While two[48,
50] of these studies specified the statistical method used to test the PHA, none actually
reported their result. One study[43] reported testing for collinearity but reported neither the
technique used nor the results. Eight studies [45, 51, 55, 56],[43, 48, 49, 53] did not report how
many patients died during follow-up. Among these, four[45, 51, 55, 56] included more predic-
tor degrees of freedom in their multivariate model than their total sample size n divided by 10.
In addition, six studies[44, 51, 53–56] included at least one predictor that had ten or less events
in a stratum in one of their categorical variable(s). Furthermore, deficiencies in reporting were
identified in all 17 studies, including: three studies[47, 49, 53] did not report the hazard ratio
or confidence intervals, seven studies[43, 46, 48, 49, 52, 55, 56] studies did not identify the ref-
erent stratum for their categorical predictors and 12 studies[24, 41, 44–46, 49, 50, 53–57] did
not indicate the directionality of associations (shorter or longer survival).
Overall strength of evidence related to survival
Seven studies examined the preoperative clinical factors associated with survival in patients
with SSM from all sites of primary tumor including multiple myeloma (MM). A total of 20 fac-
tors were identified, among which 11 were related to the site/histology of the primary tumor
[24, 43–45, 50, 56, 57]. Two studies[24, 59] evaluated predictors of survival in patients with
SSM from all sites of primary tumors excluding MM and reported three predictors: primary
tumor Tomita Grade II and III (original classification), presence of visceral metastases and
presence of bone metastases (spinal and extraspinal). The baseline strength of evidence was
Low for preoperative prognostic factors of survival in studies that considered all sites of pri-
mary tumors including or excluding MM. When MM was included, only radioresistant site of
primary tumor had a final strength of evidence of Low. All other predictors related to the site
of primary tumor were downgraded to Very low due to high risk of bias related to inconsis-
tency of results. Non-ambulatory status and CCIS 2 maintained a final strength of evidence
of Low while the remaining seven predictors were downgraded to Very low for at least high
Symptomatic spinal metastasis – a systematic review
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risk of bias. The final strength of evidence for the three predictors of survival for all primaries
excluding MM was also Very low for at least high risk of bias (Table 3).
Various preoperative factors of survival were identified in multivariate analysis in specific
groups of SSM patients. Although two studies examined the preoperative factors of survival in
patients with SSM from prostate cancer, they did not consider the same predictors. KPS 50–
70%[54], Gleason score > 8[49], total number of metastases > 5[49], presence of lymph node
metastases at the time of surgery[49] and degree of canal compression > 25%[49] had a Low
strength of evidence at baseline and their respective final strength of evidence was Very low
due to high risk of bias (Table 3). Based on two studies[41, 51], the four predictors of survival
for SSM resulting from NSCLC also had a Low strength of evidence at baseline. All predictors
were downgraded to a Very low final strength of evidence: low performance status and 14
days from onset of motor deficit to surgery because of high risk of bias and 3 vertebral
metastases and presence of visceral metastasis because of high risk of bias and inconsistency
(Table 3). Preoperative prognostic factors in patients with (1) unknown site of primary tumor
at the time of SSM surgery, (2) breast cancer, (3) HHC, (4) lung cancer, 60 years old with
SSM from heterogenous primary tumors were derived from a single study, all of which had a
Low strength of evidence at baseline. The final strength of evidence for predictors of survival in
breast cancer[48] was Low while all the others[46, 47, 52, 55] were downgraded to Very low
due to high risk of bias[46, 47, 52, 55] and imprecision[47] (Table 4).
Discussion
Summary of findings
To our knowledge, this is the first systematic literature review that has sought to determine
the key preoperative predictors of survival (KQ1), neurologic (KQ2), functional (KQ3), and
HRQoL (KQ4) outcomes in patients with SSM who underwent surgical treatment. This sys-
tematic review identified 17 studies related to our KQ1 that conducted multivariate analysis
and reported a total of 46 preoperative prognostic factors of survival in surgical SSM patients.
All 17 prognostic studies were rated as having a moderately high risk of bias (Class III evi-
dence). The final strength of the overall body of evidence was graded low for 7 and very low for
the remaining 39 predictors of survival.
In spite of performing a literature search designed to maximize sensitivity, this review was
only able to identify studies addressing KQ1. Six studies examined the clinical prognostic fac-
tors of functional status (KQ3) and one study isolated predictors of HRQoL (KQ4), but these
studies were excluded because they included surgical and/or postoperative predictors. Inclu-
sion of such predictors in the multivariate analysis runs the risk of precluding relevant
preoperative predictors from either being selected in the final model or showing statistical sig-
nificance. Also, final models that retain surgical/postoperative predictors are not relevant in
the preoperative period, which is the critical time-point for clinical decision-making. There-
fore, while this review had limited success in establishing preoperative prognostic factors of
survival, it also highlights the dearth of evidence related to predictors of neurologic, functional,
and HRQoL outcomes in surgical SSM patients.
Methodological considerations and recommendations
Due to the nature of cohort studies, prognostic data from these will be biased and may not be
generalizable to patients with spinal metastases. Cohort studies are often limited by cost and
timescales, and significant losses to follow-up. Spinal centers may cover large geographical
areas, and patients may be transferred elsewhere for subsequent oncological treatments. Fail-
ure to return for spinal clinic follow-up at prearranged appointment times may be due to travel
Symptomatic spinal metastasis – a systematic review
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constraints, the patient may be too unwell, undergoing other treatments, or they may prefer to
be reviewed by local oncologists instead.
In addition, survival analyses are inherently complex, and our attempt to synthesize this
group of 17 such studies was challenging due to considerable heterogeneity in patient samples
and prognostic factors investigated. Furthermore, the design and reporting of the statistical
analyses were problematic in many studies, leading to a moderately high risk of bias and diffi-
culty interpreting the results. Since multivariate techniques applied to systematically collected
data from a specific patient population may improve clinical prediction by identifying key
prognostic factors[23, 60] and it is likely that various factors conjointly influence clinical
outcomes such as survival or HRQoL, performing multivariate analysis was one of our inclu-
sion criteria. Conducting multivariate analysis not only helps control for confounders, thus
enhancing the confidence in the validity of the study results[61], but also provides an estimate
of the actual effect size, offering both a clinical and statistical assessment of the impact of each
factor on the outcome variable.[62]
Prognostic studies should be designed and conducted to minimize potential biases related
to six domains.[35] (1) Study participants and sample: Data should be collected prospectively.
Patients should be at a common point in the course of their disease. Patient sample assembly
should include method, period, place of recruitment, and eligibility criteria. Patient sample
should be adequately described for key characteristics. (2) Study attrition: The follow-up
period should be long enough for the outcome(s) of interest to occur. The proportion of par-
ticipants completing the study should be reported and adequate for the study design and
analyses. If applicable, the reason(s) for loss to follow-up should be recorded. Account and
measurement of (3) prognostic factors, (4) outcomes and (5) confounding factors: the defini-
tion and method of measurement of prognostic factors, outcomes and confounders should be
Table 4. Overall body of evidence for preoperative predictors of survival in surgical SSM patients from a single study.
Negative preoperative predictors Baseline strength Up- / Downgrade Final strength of evidence
Breast cancer [48]
Longer time interval from cancer diagnosis to surgery (year) Low Low




Serum albumin <37 g/L Low -1: risk of bias Very low
Lactate dehydrogenase 200 U/L
Lung cancer: NSCLC and SCLC[55]
Presence of visceral metastasis Low -1: risk of bias Very low
14 days between development of motor deficits due to SSM to surgery
Non-ambulatory status
 60 years old patients[46]
Original Tokuhashi score < 9 points Low -1: risk of bias Very low
Rapid- or moderate-growing primary tumour Tomita grade
Unknown site of primary tumor at the time of SSM surgery[47]
Cervical spinal location Low • -1: risk of bias
• -1: precision
Very low
Presence of extraspinal disease at presentation
Frankel A, B, C
Abbreviations (alphabetical order): NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; SSM: symptomatic spinal metastasis
doi:10.1371/journal.pone.0171507.t004
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clearly described, valid, reliable and appropriate. An adequate proportion of the study sample
should have complete data for prognostic factor, outcome and confounders, and if imputation
is used for missing data, the method should be described and appropriate. (6) Analysis: The
statistical analyses, including model selection and building, should be suitable for the study
design, assumptions should be verified, and if applicable, adequate adjustment for confound-
ing should be undertaken. Finally, all results should be adequately reported.[35, 63, 64]
The development of clinical prediction rules
While there is no well recognized CPR for HRQoL, the variable prognostic ability of current
CPRs of survival[24–26] in this patient population may be related to the fact that patients who
are deemed surgical candidates are fundamentally different, with overall greater life expectancy
and fewer comorbidities, than patients selected for conservative or radiotherapy treatment
alone. Selecting relevant predictors from a larger set of candidate predictors is one of the steps
involved in the first phase of development of CPRs; these predictors are typically derived from
best literature evidence. These CPRs could be of high clinical value by providing more accurate
estimates of survival and HRQoL after surgery, helping not only to guide therapeutic decision-
making during informed consent discussions, but also patients to form more realistic expecta-
tions relative to surgical outcomes.
Strengths and limitations
The systematic literature review was conducted in accordance with the PRISMA guidelines.
We assessed the quality of the studies and evaluated the strength of the overall body of evi-
dence for each preoperative predictor identified through our sensitive and rigorous literature
review. However, this review aimed to identify predictors of a wide range of outcomes, com-
bining the results of studies with substantial heterogeneity in the prognostic factors, outcome
measures, and patient populations that were assessed, which may constitute a problem with
internal validity. Furthermore, our a priori eligibility criteria were relatively narrow in their
requirement and may have excluded studies that produced pertinent findings.
In predicting future outcomes by using patient data available at presentation, there will
always be a degree of randomness or “chaos” in the system affecting clinical outcomes and sur-
vival.[65] Although we may improve prediction by establishing better methodology, there will
always be random variability between studies and between patients, and there comes a point
where studying preoperative patient variables too closely may not be helpful, due to the inher-
ent variation that does not improve regardless of increasing sample size.
Conclusions
Life expectancy and HRQoL are cornerstones to clinical decision-making in surgical SSM
patients. Based on the results of 17 pertinent studies, this systematic review found a low overall
strength of evidence for seven preoperative predictors of survival and very low strength evi-
dence for 39 additional predictors. Consequently, we have low confidence that the evidence
reflects the true effect size of these predictors. Furthermore, no evidence was found for the pre-
diction of neurologic, functional, and HRQoL outcomes. Further rigorously conducted pro-
spective studies are needed to better understand what preoperative factors are prognostic of
these various outcomes, for the purpose of surgical decision-making, development of CPRs,
patient education and levering treatment expectations. Genetic analysis of tumor subtypes will
also need to be included in future prediction models, since novel chemotherapies and immu-
notherapies are showing promising influence on survival and HRQoL.
Symptomatic spinal metastasis – a systematic review
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